Skip to main content

Posts tagged with "Press Coverage"

  • Cancer

    Antibiotics: Not As Easy As They Say

    Since we were just talking yesterday about antibiotics and the misconceptions that people have about them, this is an appropriate time to take a look at an article in the popular press about antibiotic discovery. ( counts as “popular press”, for sure). The article focuses on the work of Brian Murphy at UI-Chicago, who’s do… Read More
  • Drug Development

    Idiocy On Drug Research Costs

    Here’s a piece from the Center for Economic and Policy Research that claims to have the whole high-drug-price problem figured out. It’s “incredibly inefficient research”, just so you know. How does the CEPR know, you ask? They do a comparison of the costs of research (as provided by the Center for the Study of Drug Developm… Read More
  • Press Coverage

    Statnews Launches

    I wanted to mention a new pharma/health news source, Statnews. This is a venture of the Boston Globe, recognizing that the Boston/Cambridge area has a massive presence in this field and that a dedicated news organization could do a lot here. They’ve assembled an excellent team of journalists, and anyone who’s followed science reporting… Read More
  • Cancer

    Revolutionary Miracle Breakthrough Cures

    Anyone who knows anything about drug research knows to beware terms like “miracle” or “breakthrough” when used to describe a possible new treatment. There are such things, but they’re out numbered by the press releases and clueless reports that describe every other result as an amazing advance in human knowledge. There… Read More
  • Business and Markets

    Dying By the Sword

    There have been several developments in the T*ing/Valeant world, that supposedly risk-free gravy train where you wait for others to discover the drugs, then you take over and raise the prices. An outfit called Imprimis Pharmaceuticals is moving in on Daraprim (pyrimethamine), Martin Shkreli’s infamous fifty-fold price increase drug. Shkreli&# Read More
  • Drug Prices

    Shkreli, Turing, and PhRMA

    There have been a few developments in the Turing Pharmaceuticals affair. Martin Shkreli, after given several fantastically annoying interviews, finally reversed course and said that the company will lower the price of Daraprim (pyrimethamine). He is not, at the moment, saying what the price will be lowered to: perhaps to merely ten times the previo… Read More
  • Drug Development

    Optimistic Stem Cell Quotes

    How does the press cover stem cell work? You probably already know the answer to that one, but here’s proof: this paper examines the media coverage from 2010 to 2013, and finds that “highly optimistic” timelines for translation to the clinic are the rule. Unfortunately, they also find that quotes from scientists are the main… Read More
  • Press Coverage

    A Pharma Expert Weighs In

    In case you were wondering, Chuck Norris does not know what he’s talking about when he talks about drug discovery and development. In other news, I don’t know what I’m talking about when I talk about martial arts or tv/movie production. But I’m not trying to tell Chuck Norris about those things, now, am I?… Read More
  • Press Coverage

    The New York TImes on Drug Discovery

    The New York Times Magazine has a piece on the current problems with drug discovery. I was interviewed by the author, and get I quoted at one point. Nothing in the article will amaze any regular reader here, but it’s probably the first time many of the magazine’s readership are hearing about many of these… Read More
  • Clinical Trials

    Studies Show? Not So Fast.

    Yesterday’s post on yet another possible Alzheimer’s blood test illustrates, yet again, that understanding statistics is not a strength of most headline writers (or most headline readers). I’m no statistician myself, but I have a healthy mistrust of numbers, since I deal with the little rotters all day long in one form or another. Read More